Comment from United Porphyrias Association

Summary: The United Porphyrias Association, a patient advocacy organization, supports the Commissioner’s National Priority Voucher (CNPV) Pilot Program but urges the FDA to improve its implementation. The organization recommends incorporating a structured patient-informed perspective into the Review Council, applying science-based flexibility for rare disease review, and evaluating the program's success based on patient-relevant outcomes and clarity rather than just review timelines.